scholarly journals Treatment of renal colic with injectable aspirin [Aspegic]

1997 ◽  
Vol 3 (2) ◽  
pp. 296-296
Author(s):  
Falih M. Al Obadi ◽  
Jinan I. Mobarak ◽  
Abdullah M. Jawad
Keyword(s):  
Adverse Effects ◽  
Emergency Treatment ◽  
Renal Colic ◽  
Response To Treatment ◽  
Complete Relief ◽  
Excellent Response ◽  
End Of Treatment

Forty-four [44] patients with severe renal colic were studied for their response to 500 mg injectable aspirin [Aspegic] administered intravenously twice daily for two days. It was found that 22.7% reported complete relief from pain after the first injection and 72.7% showed various degrees of improvement. In the overall assessment at the end of treatment, 63.6% showed an excellent response. Two patients did not show any response to treatment. Nineteen patients [43.2%] had felt or seen the stone pass out in urine, and none experienced any major adverse effects. Aspegic could be a useful drug in emergency treatment of severe renal colic

scholarly journals Intravenous paracetamol versus ketorolac for pain attenuation in patients with renal colic; a randomized, single blind and controlled clinical trial

2020 ◽  
Vol 9 (2) ◽  
pp. e10-e10
Author(s):  
Arash Ardestani Zadeh ◽  
Davood Arab ◽  
Mohammadreza Moonesan ◽  
Majid Mirmohammadkhani ◽  
Pouya Morid
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Renal Colic ◽  
Vital Signs ◽  
Analgesic Efficacy ◽  
Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Intravenous Paracetamol ◽  
Significant Difference ◽  
Single Blind

Introduction: Pain control is an essential care for patients with renal colic in emergency wards. Objectives: This study aimed to compare the analgesic efficacy of intravenous (IV) paracetamol (PC) versus ketorolac (KET) for patients with renal colic. Patients and Methods: In a randomized controlled clinical trial, 110 patients with renal colic referred to the emergency department of Kosar hospital, Semnan between October 2015 and June 2016 were selected. Eighty-eight patients were divided into two groups (44 patients in each group) of PC (1 g/IV) and KET (30 mg/IV). One patient in each group was excluded during the study. Vital signs and pain severity (measured by visual analogue scale [VAS]) of all patients were recorded at admission time 0, 20, 40 and 60 minutes after treatment. Then, the results were compared in two groups. Results: The results showed that at the time of 0, 20, 40 and 60 minutes after the administration of the PC and KET drugs, no significant difference was seen in severity of pain based on VAS score between the two groups (P<0.05). Moreover, there were no significant differences in the vital signs of two groups (P<0.05). No adverse effects were reported in each group. Conclusion: In conclusion, the use of IV-PC and KET in patients with renal colic had similar pain relieving effects without any adverse effects.

The Role of Spontaneous Repetitions During Treatment of Morphosyntactic Forms for Children With Developmental Language Disorder

2021 ◽  
Vol 64 (10) ◽  
pp. 3995-4003
Author(s):  
Katrina Nicholas ◽  
Elena Plante ◽  
Rebecca Gómez ◽  
Rebecca Vance
Keyword(s):  
Treatment Effect ◽  
Language Disorder ◽  
Effect Sizes ◽  
Response To Treatment ◽  
Structural Priming ◽  
Developmental Language Disorder ◽  
End Of Treatment ◽  
Correct Form ◽  
Treatment Gains

Purpose Children with developmental language disorder sometimes spontaneously repeat clinician models of morphemes targeted for treatment. We examine how spontaneous repeating of clinician models in the form of recasts associates with improved child production of those emerging morphemes. Method Forty-seven preschool children with developmental language disorder participated in Enhanced Conversational Recast therapy and were monitored for spontaneous repetitions of morphemes modeled by the clinician through conversational recasting. We calculated proportion of correct and incorrect productions elicited during treatment and for generalization probes as well as treatment effect sizes. We then used odds ratios to determine the probability that a spontaneous repetition may precede treatment gains and calculated correlations of correct repetitions with correct in-treatment productions of targets and treatment effect sizes. Results Spontaneous repetitions were highly likely to happen just prior to meaningful treatment progress. Children with higher frequencies of correct spontaneous repetitions of morpheme targets also showed higher frequencies of correct productions of these forms during the course of treatment. Furthermore, children with an earlier onset of repetitions and higher frequencies of correct repetitions showed overall larger effect sizes at the end of treatment. Conclusions Children's use of correct forms in their repetitions may serve as a self-scaffold for mastering productions of the correct form via structural priming mechanisms. Tracking spontaneously repeated targets may be a useful milestone for identifying response to treatment.

scholarly journals New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients

2015 ◽  
Vol 60 (2) ◽  
pp. 833-837 ◽  
Author(s):  
María Gabriela Álvarez ◽  
Yolanda Hernández ◽  
Graciela Bertocchi ◽  
Marisa Fernández ◽  
Bruno Lococo ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Effects ◽  
Liver Enzymes ◽  
Main Criterion ◽  
Short Term ◽  
Follow Up Study ◽  
End Of Treatment ◽  
Chronic Chagas Disease

ABSTRACTThere is a clinical need to test new schemes of benznidazole administration that are expected to be at least as effective as the current therapeutic scheme but safer. This study assessed a new scheme of benznidazole administration in chronic Chagas disease patients. A pilot study with intermittent doses of benznidazole at 5 mg/kg/day in two daily doses every 5 days for a total of 60 days was designed. The main criterion of response was the comparison of quantitative PCR (qPCR) findings prior to and 1 week after the end of treatment. The safety profile was assessed by the rate of suspensions and severity of adverse effects. Twenty patients were analyzed for safety, while qPCR was tested for 17 of them. The average age was 43 ± 7.9 years; 55% were female. Sixty-five percent of treated subjects showed detectable qPCR results prior to treatment of 1.45 (0.63 to 2.81) and 2.1 (1.18 to 2.78) parasitic equivalents per milliliter of blood (par.eq/ml) for kinetoplastic DNA (kDNA) qPCR and nuclear repetitive sequence satellite DNA (SatDNA) qPCR, respectively. One patient showed detectable PCR at the end of treatment (1/17), corresponding to 6% treatment failure, compared with 11/17 (65%) patients pretreatment (P= 0.01). Adverse effects were present in 10/20 (50%) patients, but in only one case was treatment suspended. Eight patients showed mild adverse effects, whereas moderate reactions with increased liver enzymes were observed in two patients. The main accomplishment of this pilot study is the promising low rate of treatment suspension. Intermittent administration of benznidazole emerges a new potential therapeutic scheme, the efficacy of which should be confirmed by long-term assessment posttreatment.

Serum Levels and Pharmacokinetic of Rituximab in Bi-Weekly R-CHOP in Elderly Patients with DLBCL Treated in the RICOVER-60 Trial.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2748-2748 ◽  
Author(s):  
Marcel Reiser ◽  
Michael K. Wenger ◽  
Christina Nickenig ◽  
N. Peter ◽  
Christian Kuhn ◽  
...  
Keyword(s):  
The Netherlands ◽  
Elderly Patients ◽  
Half Life ◽  
Serum Levels ◽  
Response To Treatment ◽  
Aggressive Lymphoma ◽  
Serum Samples ◽  
Bulky Disease ◽  
End Of Treatment ◽  
Dose Dense

Abstract Background: The combination of Rituximab and CHOP is considered the standard of treatment for DLBCL in elderly patients (pts) but there is hardly any data on the pharmacokinetic of Rituximab in aggressive lymphoma pts. Objective: To study serum levels and pharmacokinetic properties of Rituximab when combined with dose dense CHOP-14 in elderly DLBCL patients Methods: Blood samples of 18 pts were taken before and after Rituximab-infusion at each chemotherapy cycle. Additional samples were taken after the end of treatment and at the following timepoints: after 1 week, 1 month, 2 months, 3 months, 6 months and 9 months, respectively. Serum samples were taken within a maximum of 30 min, centrifuged at 1000 g for 10 min (room temperature) and stored at −20 degrees C. Batch samples were shipped to Xendo Lab., Groningen, The Netherlands, and analysed. The measured values were analysed by pharmakokinetic software MW/PHARM, version 3.50; (MediWare, 9800 AB Zuidhorn, The Netherlands) Additionally, a simulation of expected Rituximab-PK was performed taking into account 5 clinical trials, totalling 3777 observations in 264 patients mostly FL. Results: Median (range) age of pts was 69 (61–79) years. 10/18 pts had advanced stage (III/IV), 4/18 pts had bulky disease. Pts received a median (range) dose of 683 (545–791) mg Rituximab/cycle. Response to treatment was 15/18 CR/Cru, 2/18 PR,1/18 PD. The median (range) of trough serum Rituximab-levels (μg/ml) before each cycle were: #1 0(0–0); #2 39(18–61); #3 74(47–109); #4 95(40–136); #5 113(55–157); #6 114(12–518); #7 125(72–207);#8 117(75–304). After therapy Rituximab-levels were: 163(68–248) at 1 week; 101(44–163) at 1 month, 55(11–122) at 2 months, 33(6–577) at 3 months; 5(0–103) at 6 months, 0.7(0–128) at 9 months. 7 pts were evaluable at 9 months with 4/7 pts showed detectable Rituximab-levels. Thus, actual serum levels detected fit exactly the model calculated from data of patients with FL. A preliminary PK analysis of Rituximab according to a two-compartment model showed a long median (range) serum half-life (t 1/2) of 765 h (543–1092). Conclusion: In the dose dense bi-weekly regimen R-CHOP-14 Rituximab-serum levels increased slowly up to cyle 5. During cycle 5– 8 the serum Rituximab-levels reached a plateau and decreased constantly after the end of treatment with detectable levels even after 9 months and a long serum half-life. Increasing serum levels in the first four cycles are due to saturation kinetics of Rituximab. Based on this data the German High Grade NHL Study Group (DSHNHL) further investigates a dose escalation of Rituximab in the first cycles in order to improve treatment outcome.

Acupuncture for Treatment of Noncyclic Breast Pain: A Pilot Study

2011 ◽  
Vol 39 (06) ◽  
pp. 1117-1129 ◽  
Author(s):  
Lori A. Thicke ◽  
Jennifer K. Hazelton ◽  
Brent A. Bauer ◽  
Carl W. Chan ◽  
Elizabeth A. Huntoon ◽  
...  
Keyword(s):  
Pilot Study ◽  
Controlled Trial ◽  
Brief Pain Inventory ◽  
Well Being ◽  
Pain Interference ◽  
Response To Treatment ◽  
Breast Pain ◽  
Breast Clinic ◽  
End Of Treatment ◽  
Average Pain

Noncyclic breast pain is a common breast disorder prompting women to seek medical evaluation. We aimed to perform a pilot study on the relief of noncyclic breast pain using acupuncture. Thirty-seven women seen at a diagnostic breast clinic between April 2003 and January 2009 were enrolled. Treatment consisted of four acupuncture sessions over two weeks, with three months of follow-up. Response to treatment was measured with use of a breast pain questionnaire, a quality of life (QOL) questionnaire, and the Cleeland Brief Pain Inventory (BPI) assessed at baseline, end of treatment, and three months after treatment. Data were analyzed using standard descriptive statistics. Twenty-two patients completed four acupuncture sessions. Pain described as throbbing and heavy decreased significantly after acupuncture (p = 0.04 and p = 0.03, respectively). After treatment, pain scores (on the 10-point BPI scale) decreased by an average of 3.5 points for the worst pain during the previous month (p = 0.001), by 2.7 points for average pain (p < 0.001), and by 2.3 points for pain interference (p = 0.002). The percentage of patients reporting a clinically meaningful decrease of 2 points from baseline to the end of treatment included 67% (12/18) for the worst pain, 65% (11/17) for average pain, and 56% (10/18) for pain interference. QOL data showed no improvement in QOL measures (mental, physical, emotional, social, or spiritual well-being). The results of this preliminary study suggest that a randomized controlled trial may be warranted to evaluate the effect of acupuncture on noncyclic breast pain, as well as the optimal frequency of acupuncture treatments.

scholarly journals Topical Amitriptyline-Ketamine for Treatment of Rectal, Genital, and Perineal Pain and Discomfort

2012 ◽  
Vol 6;15 (6;12) ◽  
pp. 485-488
Author(s):  
Mark D. P. Davis
Keyword(s):  
Adverse Effects ◽  
Pelvic Pain ◽  
Retrospective Review ◽  
Medical Records ◽  
Academic Medical Center ◽  
The United States ◽  
High Rate ◽  
Perineal Pain ◽  
Complete Relief ◽  
Patient Reported

Background: Pain in the rectal, genital, and perineal area is a common condition treated by pain physicians. These chronic pain syndromes are therapeutically challenging because both interventional and drug therapies often are ineffective. Objectives: To determine if pelvic pain can be treated effectively with compounded topical amitriptyline-ketamine. Study Design: A retrospective review of medical records. Setting: A single academic medical center in the United States. Methods: We identified all patients treated with topical amitriptyline-ketamine from January 1, 2004, through November 28, 2011. Medical records were evaluated to determine the diagnosis for which the medication was prescribed. Treatment efficacy and any adverse effects were recorded. Results: Of the 1,068 patients who received amitriptyline-ketamine, 13 had the medication prescribed for genital, rectal, or perineal pain and had medication efficacy recorded. These patients were treated with a topical combination of amitriptyline 1-2% and ketamine 0.5%. Of these 13 patients, one (8%) had complete relief, 6 (46%) had substantial relief, 4 (31%) had some relief, and 2 (15%) had no response. One patient reported occasional irritation while using topical amitriptyline-ketamine with lidocaine; no other patients reported local or systemic adverse effects. Limitations: Retrospective review; lack of uniform system for pain grading; concurrent use of other medications. Conclusions: Topical amitriptyline-ketamine provided a high rate of pain relief with a low adverse-effect burden in patients with pelvic pain. This topical medication could offer an effective, noninvasive, nonopioid therapy for pain in the rectum, perineum, and genitals. Key words: Amitriptyline, rectal, compounded medication, genital, ketamine, pain, pelvic, perineal.

scholarly journals Chromogranin A and serotonin for evaluation of treatment efficacy of neuroendocrine tumors

2020 ◽  
Vol 47 (8) ◽  
pp. 685-690
Author(s):  
N. V. Lyubimova ◽  
Yu. S. Timofeev ◽  
T. K. Churikova ◽  
A. A. Markovich ◽  
G. S. Emelianova ◽  
...  
Keyword(s):  
Partial Response ◽  
Neuroendocrine Tumors ◽  
Treatment Efficacy ◽  
Chromogranin A ◽  
Response To Treatment ◽  
Serial Measurement ◽  
End Of Treatment ◽  
Disease Behavior ◽  
Clinically Significant ◽  
Sensitive Marker

Background: The utility of biochemical markers in the monitoring of treatment efficacy in patients with neuroendocrine tumors (NETs) goes beyond any doubt. However, there are still no clear criteria for the assessment of clinically significant abnormalities of the main NET biomarkers chromogranin A (CgA) and serotonin. Aim: To evaluate the value of serial measurement of serum CgA and serotonin in the monitoring of the treatment effect in NET patients. Materials and methods: Serum CgA and serotonin levels were measured in 107 patients with NETs at baseline and at 3–4 weeks after the end of treatment (chemotherapy, biotherapy), as well as in 60 healthy controls. We used enzyme immunoassay based on Chromogranin A NEOLISA (Euro Diagnostica) and Serotonin ELISA (IBL International GmbH) test systems. Results: There was an association between CgA levels and the efficacy of chemotherapy in NET patients. With progression of the disease, median CgA increased significantly from 412 to 2679 ng/mL (p = 0.012), whereas in the patients with partial response it decreased from 811 to 254 ng/mL (p = 0.023). The ROC analysis showed the 33% cut-off for significant CgA changes for progression, with sensitivity of 80.0% and specificity of 95.6%. A decrease (of more than 33% compared to baseline levels) or absence of significant CgA changes was associated with stabilization of the disease or with partial response to treatment. Significantly decreased CgA levels were found in 75.0% cases of partial response and 43.48% of stabilized patients, whereas the absence of any significant changes in 25 and 66.7%, respectively. There was no association between serotonin levels and the disease behavior under treatment.Conclusion: CgA could be used as a sensitive marker of NET progression on chemotherapy.

scholarly journals Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Susan Shafiei ◽  
Mehrdokht Sadrolodabaei ◽  
Atena Aghaei ◽  
Narjess Ayati ◽  
Samira Zare Namdar ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Response To Treatment ◽  
Control Groups ◽  
Excellent Response ◽  
Significant Difference ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Background: Familial NMTCs are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. Objectives: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of familial and sporadic NMTC. Methods: This is a retrospective study in patients with familial NMTC (at least one other first-degree relative involved) who were treated with surgery, followed by radio-iodine therapy (RIT) without consideration of its familial origin. Response to treatment was compared between familial NMTC and age, sex, and TNM stage-matched non-familial NMTC (control group). Response to treatment was assessed one and two years after RIT, and time to excellent response was identified. Results: Out of 2,944 NMTC patients, 81 (2.75%) patients had familial NMTC. We compared 66 patients with familial NMTC and 66 sporadic NMTC patients. There was no significant difference in first thyroglobulin, initial and accumulative iodine dose, and additional treatments (additional surgery and radiotherapy) between patients and controls. Although no significant difference was noted in one and two years’ responses to treatment between the case and control groups, familial NMTC patients required more time to achieve excellent response (26.7 ± 24.9 versus 15.9 ± 9.0 months, P = 0.01). No significant difference was noted between familial NMTC patients with two or more than two involved relatives. Conclusions: Our study showed that if patients with familial NMTCs were treated in the same way as non-familial patients, the time to excellent response would be significantly longer, even when they have only one other involved relative.

scholarly journals Automatic Prediction and Assessment of Treatment Response in Patients with Hodgkin’s Lymphoma Using a Whole-Body DW-MRI Based Approach

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 702
Author(s):  
Valentina Brancato ◽  
Marco Aiello ◽  
Roberta Della Pepa ◽  
Luca Basso ◽  
Nunzia Garbino ◽  
...  
Keyword(s):  
Treatment Response ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Response To Treatment ◽  
Whole Body ◽  
Positron Emission ◽  
End Of Treatment ◽  
Tumor Load ◽  
Magnetic Resonance Imaging Mri

The lack of validation and standardization represents the main drawback for a clear role of whole-body diffusion weighted imaging (WB-DWI) for prediction and assessment of treatment response in Hodgkin’s lymphoma (HL). We explored the reliability of an automatic approach based on the WB-DWI technique for prediction and assessment of response to treatment in patients with HL. The study included 20 HL patients, who had whole-body positron emission tomography (PET)/ magnetic resonance Imaging (MRI) performed before, during and after chemotherapy. Using the syngo.via MR Total Tumor Load tool, we automatically extracted values of diffusion volume (DV) and its associated histogram features by WB-DWI images, and evaluated their utility in predicting and assessing interim and end-of-treatment (EOT) response. The Mann–Whitney test followed by receiver operator characteristic (ROC) analysis was performed between features and their inter-time point percentage differences for patients having a complete or partial treatment response, revealing that several WB-DWI associated features allowed for prediction of interim response and both prediction and assessment of EOT response. Our proposed method offers huge advantages in terms of saving time and work, enabling clinicians to draw conclusions relating to HL treatment response in a fully automatic way, and encloses, also, all DWI advantages compared to PET/ computed tomography (CT).

Sign in / Sign up

Export Citation Format

Share Document